Expert Interview
Discussing the potential of Petosemtamab in treating Head and Neck Cancer (HNSCC) and how it compares to other EGFR biologics
Ticker(s): MRUSInstitution: MD Anderson
- Professor of Medicine Thoracic-Head & Neck Med Oncology at The University of Texas MD Anderson Cancer Center.
- Manages 20 patients with HNSCC per week.
- Research focused on defining the biological and molecular effects of the modulation of signal transduction pathways in lung, head and neck, and HPV+ cancers; has defined novel mechanisms of sensitivity and resistance to kinase inhibitors.
Could you first give a brief introduction of your clinical expertise and details about your practice setting?
Added By: ben_adminHow many patients with head and neck cancer do you treat? Do you treat any with metastatic disease? What % is metastatic?
Added By: ben_adminWhat are you typically giving patients right now on the front line? What is your treatment algorithm in making these decisions?
Added By: ben_adminCan you talk about your familiarity with EGFR targeting medications and their efficacies?
Added By: ben_adminHave you prescribed bispecifics (ex. blinatumomab, emicizumab, amivantamab) before and if so in what setting? What has been your experience?
Added By: ben_adminOn clinical trials.org, there are no sites yet recruiting in the US. Does this concern you at all for FDA approval moving forward or Merus’ ability to recruit an adequate number of patients?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
